# 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

> **NCT06329830** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Baptist Health South Florida**

## Conditions studied

- Metastatic Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **DRUG:** Niraparib abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06329830
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding for the study was withdrawn.
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329830, "177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06329830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*